Peter Marks

Mr. Peter A. Marks is an Independent Non-Executive Director at Alterity Therapeutics Ltd., a Chairman at Newburyport Partners Pty Ltd. and a Principal at Halcyon Corporate Pty Ltd. He is on the Board of Directors at Evergold Minerals Ltd., Palisade Metals Ltd., Noxopharm Ltd., Alterity Therapeutics Ltd., rivusTV, Electriq Global Ltd. and Emefcy Ltd. Mr. Marks was previously employed as a Non-Executive Director by Elsight Ltd., a Non-Independent Non-Executive Director by Nyrada, Inc., a Non-Executive Director by Fluence Corp.
Ltd., a Non-Executive Director by Emefcy Group Ltd., a Non-Executive Chairman by Savcor Group Ltd., a Non-Executive Director by Armadale Capital Plc, an Executive Chairman by Respiri Ltd., a Director-Corporate Finance by Burdett Buckeridge & Young Ltd., an Associate Director by McIntosh Securities, and a Chairman by Medic Vision Ltd. He also served on the board at KPMG Corporate Finance (Australia) Pty Ltd., Momentum Funds Management Pty Ltd. and Peregrine Corporate Ltd. He received his undergraduate degree from Monash University, a graduate degree from Monash University and an MBA from the University of Edinburgh Business School.